CoChat

Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)

Capell, Warren H., Bonaca, Marc P., Nehler, Mark R., Chen, Edmond, Kittelson, John M., Anand, Sonia S., Berkowitz, Scott D., Debus, Eike Sebastian, Fanelli, Fabrizio, Haskell, Lloyd, Patel, Manesh R., Bauersachs, Rupert, Hiatt, William R. · 2018 · American Heart Journal
Cited by 131

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background: Patients with peripheral artery disease (PAD) undergoing a lower‐extremity revascularization are at heightened risk for ischemic cardiac and limb events. Although intensification of antithrombotic therapy after revascularization has demonstrated benefit in coronary disease populations, this approach has not been well studied or shown consistent benefit in PAD. Recent trial evidence demonstrated that a treatment strategy of rivaroxaban added to background antiplatelet therapy reduced ischemic risk in patients following recent acute coronary syndromes, as well as in patients with stable atherosclerotic vascular disease. Whether these benefits extend to the population of patients with symptomatic lower‐extremity PAD undergoing revascularization is the objective of the VOYAGER PAD trial. Study design: VOYAGER PAD is an international randomized, double‐blind, placebo‐controlled trial to evaluate the efficacy and safety of rivaroxaban in symptomatic PAD patients undergoing a peripheral surgical and/or endovascular revascularization. Patients are randomized in a 1:1 ratio to either rivaroxaban 2.5 mg twice daily or placebo, on a background of low‐dose aspirin (100 mg daily). In addition, the use of a limited course of P2Y12 inhibition is allowed at the discretion of the site investigator. The primary efficacy end point is a novel composite of myocardial infarction, ischemic stroke, cardiovascular death, acute limb ischemia, and major amputation of vascular etiology. The primary safety end point is major bleeding according to the Thrombolysis in Myocardial Infarction definition. Enrolment began in August 2015 and will complete randomization of at least 6,500 patients by January 2018. This event‐driven trial is expected to observe outcomes over a mean patient follow‐up of 30 months. Conclusions: VOYAGER PAD is evaluating the efficacy of rivaroxaban added to background antiplatelet therapy to reduce major cardiovascular and limb ischemic vascular outcomes in the high‐risk population of PAD patients undergoing peripheral revascularization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2018.01.011

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 131

Metadata

Authors
Capell, W. H., Bonaca, M. P., Nehler, M. R., Chen, E., Kittelson, J. M., Anand, S. S., Berkowitz, S. D., Debus, E. S., Fanelli, F., Haskell, L., Patel, M. R., Bauersachs, R., & Hiatt, W. R.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2018-05
Volume
199
Pages
83-91
ISSN
0002-8703 (ISSN-L)
OpenAlex
W2793477810
Cited by
131
References
11
FWCI
21.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.